Cite
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
MLA
Gadgeel, S., et al. “Alectinib versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer: CNS Efficacy Results from the ALEX Study.” Annals of Oncology, vol. 29, no. 11, Nov. 2018, pp. 2214–22. EBSCOhost, https://doi.org/10.1093/annonc/mdy405.
APA
Gadgeel, S., Peters, S., Mok, T., Shaw, A. T., Kim, D. W., Ou, S. I., Pérol, M., Wrona, A., Novello, S., Rosell, R., Zeaiter, A., Liu, T., Nüesch, E., Balas, B., & Camidge, D. R. (2018). Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Annals of Oncology, 29(11), 2214–2222. https://doi.org/10.1093/annonc/mdy405
Chicago
Gadgeel, S, S Peters, T Mok, A T Shaw, D W Kim, S I Ou, M Pérol, et al. 2018. “Alectinib versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer: CNS Efficacy Results from the ALEX Study.” Annals of Oncology 29 (11): 2214–22. doi:10.1093/annonc/mdy405.